Abraxis Articles
Celgene to buy Abraxis in $2.9 billion cash and stock deal, bagging the latter’s cancer drug Abraxane
1 July 2010
Abraxis names Leon Moulder as CEO
7 May 2009
Abraxane rights cost deepens Abraxis' loss
16 March 2009
Abraxane launched in Germany
9 February 2009
Abraxis appoints Merck's Lax Van der Ploeg as SVP
26 January 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
18% of BC patients see complete response with Abraxane regimen
22 December 2008
Abraxis launches Abraxane in EU
22 December 2008
Abraxis seeks to reacquire US Abraxane marketing rights from AZ
1 December 2008
Cenomed presents preclinical data on lead drugs
24 November 2008
Abraxane gains marketing OK in Australia
27 October 2008
Cenomed/TorreyPines in licensing deal
13 October 2008
NCCN to test Abraxane for SPARC benefits
13 October 2008
Abraxis signs deal for 4 products with ProMetic
15 September 2008
Biocon/Abraxis debut Abraxane in India
28 July 2008
Abraxis to appeal ruling on Elan patent
23 June 2008
Abraxis reports Phase I results for Abraxane
28 April 2008
Abraxis pays initial $15M for Shimoda
14 April 2008
APP's 4th-qtr net profit falls 70% after spinout
24 March 2008
Taiho submits Japanese NDA for Abraxis BioSci's Abraxane
24 March 2008
Abraxis licenses Abraxane to Green Cross for Korea
3 December 2007
Abraxane gets CHMP nod for breast cancer
29 October 2007
Abraxis gains two FDA OKs for fludarabine
22 October 2007
Abraxis gains expedited appro of generic cefotetan
20 August 2007
US FDA approves Abraxis' sNDA for oxycotin
13 August 2007
Abraxis out-licenses Abraxane for India
13 August 2007
Abraxis BioScience and firm Cenomed establish JV
14 May 2007
BioScience closes on deal to buy Pfizer's Cruce Davila unit
26 February 2007
Abraxis launches generic ondansetron injection in USA
8 January 2007
FDA approves Abraxis' ANDA for generic combo antibiotic
4 December 2006
Genta's Genasense shows preclinical efficacy
20 November 2006
Abraxis completes purchase of AstraZeneca brands
3 July 2006
Abraxis to buy Puerto Rico unit from Pfizer
1 May 2006
APP and American Biosci complete merger to form Abraxis
24 April 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
American Bioscience names Barry Flannelly global VP, sales and marketing, Abraxis Oncology
9 January 2006
American Pharma to buy shareholder
5 December 2005
Strong results for APP's Abraxane
7 March 2005
American PP announces Abraxane launch date
7 February 2005
Showing 1-50 of 50 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
